TKI sensitivity of cells with ABL-class fusions with and without (intact) SH3 and SH2 domains. (A-C) Dose-response curves for imatinib, dasatinib, and bosutinib, respectively, of Ba/F3 models expressing SH3 domain-lacking RCSD1::ABL1 (in gray) or modified constructs including an intact SH3 and SH2 domain (RCSD1::ABL1wSH3_1/2, in blue). Values are normalized against untreated controls for each cell line and represent mean ± SEM (n = 3). (D-F) Dose-response curves for imatinib, dasatinib, and bosutinib, respectively, of primary or primary xenografted ABL-class ALL samples either with SH3 domain (in blue) or without SH3 domain (in gray). Leukemic cell survival relative to untreated controls represents the mean of 1 to 3 biological replicates.